How Many Insiders Bought Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might well want to know whether insiders have been buying or selling shares in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR).

What Is Insider Buying?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, most countries require that the company discloses such transactions to the market.

Insider transactions are not the most important thing when it comes to long-term investing. But equally, we would consider it foolish to ignore insider transactions altogether. For example, a Harvard University study found that ‘insider purchases earn abnormal returns of more than 6% per year.’

Check out our latest analysis for Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Director Eldon Mayer bought US$208k worth of shares at a price of US$10.07 per share. So it’s clear an insider wanted to buy, at around the current price. Of course they may have changed their mind. But this suggests they are optimistic. We generally consider it a positive if insiders have been buying on market, even if the share price has increased a bit since then.

In the last twelve months insiders paid US$305k for 30.00k shares purchased. Overall, Eiger BioPharmaceuticals insiders were net buyers last year. They paid about US$10.17 on average. These transactions show that insiders have confidence to invest their own money in the stock, albeit at slightly below the recent price of US$11.67. You can see the insider transactions over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGM:EIGR Insider Trading December 14th 18
NasdaqGM:EIGR Insider Trading December 14th 18

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Eiger BioPharmaceuticals Insiders Bought Stock Recently

Over the last three months, we’ve seen significant insider buying at Eiger BioPharmaceuticals. Overall, 2 insiders shelled out US$305k for shares in the company — and none sold. This is a positive in our book as it implies some confidence.

Insider Ownership of Eiger BioPharmaceuticals

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it’s a good sign if insiders own a significant number of shares in the company. Eiger BioPharmaceuticals insiders own 1.7% of the company, currently worth about US$3.8m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Eiger BioPharmaceuticals Tell Us?

It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Eiger BioPharmaceuticals stock. Of course, the future is what matters most. So if you are interested in Eiger BioPharmaceuticals, you should check out this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.